Journal
MOVEMENT DISORDERS
Volume 22, Issue 3, Pages 377-381Publisher
WILEY-LISS
DOI: 10.1002/mds.21290
Keywords
Parkinson's disease; low-density lipoprotein cholesterol; apolipoprotein E; statin; case control study
Categories
Funding
- Intramural NIH HHS [Z01 ES101986-02, Z99 ES999999] Funding Source: Medline
- NCRR NIH HHS [RR000046, M01 RR000046, M01 RR000046-41] Funding Source: Medline
- NIA NIH HHS [K23 AG021491-04, K23-AG21491, K23 AG021491] Funding Source: Medline
Ask authors/readers for more resources
The apolipoprotein E (APOE) epsilon 2 allele has been associated with both Parkinson's disease (PD) and lower low-density lipoprotein cholesterol (LDL-C). We tested the hypothesis that lower LDL-C may be associated with PD. This case-control study used fasting lipid profiles obtained from 124 PD cases and 112 controls. The PD cases were recruited from consecutive cases presenting at our tertiary Movement Disorder Clinic, and the controls were recruited from the Spouse populations of the same clinic. Multivariate odds ratios (ORs) and 95% confidence intervals (CIs) were calculated from unconditional logistic regressions, adjusting for age gender, smoking status, and use of cholesterol-lowering agents. Lower LDL-C concentrations were associated with a higher occurrence of PD. Compared with participants with the highest LDL-C (>= 138 mg/dL), the OR was 2.2 (95% Cl = 0.9-5.1) for participants with LDL-C of 115 to 137,3.5 (95% Cl = 1.6-8.1) for LDL-C of 93 to 114, and 2.6 (95% Cl - 1.1-5.9) for LDL-C of <= 92. Interestingly, use of either cholesterol-lowering drugs, or statins alone, was related to lower PD occurrence. Thus, our data provide preliminary evidence that low LDL-C may be associated with higher Occurrence of PD, and/or that statin use may lower PD occurrence, either of which finding warrants further investigation. (C) 2006 Movement Disorder Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available